CathVision Announces FDA Clearance of ECGenius™ High-Fidelity, Low-Noise EP Recording Technology
ECGenius™ Sets a New Standard for ECG Signal Acquisition, Interpretation and Therapy Support
COPENHAGEN, Denmark, May 4, 2022 — CathVision, a medical technology company developing innovative electrophysiology solutions designed to enhance clinical decision making in the EP lab, today announced the FDA 510(k) clearance of the ECGenius EP Recording System. ECGenius™, the company’s innovative EP recording technology and proprietary hardware amplifier, acquires high-fidelity, low-noise, cardiac electrograms to help electrophysiologists improve the diagnosis and treatment of complex atrial arrhythmias, including atrial fibrillation (AF).
Conventional EP recording systems typically acquire noisy and artifact-ridden electrogram signals, preventing the accurate analysis and interpretation of those signals and severely limiting the ability of electrophysiologists to correctly diagnose and devise ablation strategies. ECGenius™ delivers a necessary evolution in the quality of ECG signal acquisition, the accuracy of electrogram interpretation and the advancement of therapy support.
“ECGenius™ is setting a new standard for EP recording technology by providing clean electrical activation signals even in the most complex arrhythmias. This makes it possible to observe even minor, but significant, signal modifications,” said Dr. Peter Spector, Professor of Medicine and Engineering, and Director of Cardiac Electrophysiology, University of Vermont, Burlington, Vermont. “The system achieves minimal baseline noise without using a notch filter, minimizing EGM distortion. This provides the ability to see very low voltage signals which are often blurred or completely undetectable by the filtering of traditional recording systems. ECGenius™ is an excellent new system that will provide physicians with higher quality information with which to treat their arrhythmia patients.”
ECGenius™ is an open platform that can be seamlessly integrated into current hospital environments. The system also includes modern computer functionalities, real-time and review windows for simultaneous EP analyses and study configurations, and requires minimal user training.
“Our mission is to put electrophysiologists in the best position to improve clinical outcomes, and the basis for electrophysiology is the quality of the cardiac electrograms,” said Mads Matthiesen, CEO, CathVision. “The ECGenius™ System offers clean, unfiltered signals, and by replacing existing conventional EP recording systems, we give physicians a new way of looking at electrograms without adding more equipment to their EP labs.”
Additionally, ECGenius’s exceptional signal quality enables the future inclusion of artificial intelligence algorithms. CathVision is actively developing AI-based solutions that will be integrated into the system to facilitate electrogram interpretation and provide electrophysiologists with unprecedented levels of analysis and clinical decision support.
ECGenius1 is commercially available in the United States. For more information about ECGenius, please visit www.cathvision.com/ep-recording-enhanced/ or reach out to firstname.lastname@example.org.
1Not approved for sale in the EU.
CathVision is a medical technology company that develops electrophysiology solutions centered around an innovative EP recording system and AI algorithm platform – the ECGenius™ System. Committed to empowering physicians to make more informed clinical decisions in the EP lab, CathVision is redefining the necessity of exceptional cardiac electrical signals to diagnose, characterize, and treat the most common heart rhythm disorders. CathVision was founded in 2013 and is headquartered in Denmark with a U.S. office in Minnesota.
Follow CathVision on: Twitter and LinkedIn
U.S. Media Contacts
O: (260) 408-5383
M: (617) 233-3873